Scarica l'app Stockscreener
1.605
2.45%
-0.025
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LXRX Giù?
Forum
Previsione
Frazionamento azionario
Lexicon Pharmaceuticals Inc Borsa (LXRX) Ultime notizie
Lexicon: Q4 Earnings Snapshot - KVUE
Lexicon (LXRX) Exceeds Quarterly Revenue Expectations with Robus - GuruFocus
LEXICON PHARMACEUTICALS ($LXRX) Releases Q4 2025 Earnings - Quiver Quantitative
Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates - The Manila Times
Lexicon Pharmaceuticals Q4 Earnings Summary & Key Takeaways - Benzinga
Exploring Lexicon Pharmaceuticals's Earnings Expectations - Benzinga
LXRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
ACSL5 emerges as obesity treatment target, Lexicon Pharmaceuticals outlines - Traders Union
Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences - The Manila Times
Lexicon Pharma plans Miami fireside chat, 3 investor events in March - Stock Titan
Lexicon Pharmaceuticals (LXRX) SVP converts RSUs, withholds shares for taxes - Stock Titan
Lexicon Pharmaceuticals (LXRX) SVP converts RSUs, withholds shares for tax - Stock Titan
Lexicon Pharmaceuticals (LXRX) CMO reports RSU vesting and tax share withholding - Stock Titan
Lexicon (NASDAQ: LXRX) SVP nets shares after RSU vesting on Feb 28 - Stock Titan
Executive at Lexicon (NASDAQ: LXRX) settles tax via share withholding - Stock Titan
Lexicon (NASDAQ: LXRX) SVP exercises RSUs and withholds shares for taxes - Stock Titan
Lexicon Pharmaceuticals (LXRX) CFO logs RSU conversion and tax share withholding - Stock Titan
Lexicon (LXRX) CEO Exton exercises RSUs and withholds shares for taxes - Stock Titan
LXRX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
LXRX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Lexicon Pharmaceuticals director Debbane buys $2980 in shares - Investing.com India
Lexicon Pharmaceuticals director Debbane buys $2980 in shares By Investing.com - Investing.com Canada
Lexicon Pharmaceuticals (LXRX) director adds shares in open-market stock purchase - Stock Titan
Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026 - Caledonian Record
Lexicon Pharma plans Mar. 5 webcast on Q4 results, business update - Stock Titan
Lexicon Pharmaceuticals (LXRX) Projected to Post Earnings on Thursday - MarketBeat
Lexicon Pharma spikes after insider buy - MSN
Lexicon Pharmaceuticals (NASDAQ:LXRX) Director Raymond Debbane Acquires 100,000 Shares - MarketBeat
Lexicon Pharmaceuticals pushes for new treatments in hypertrophic cardiomyopathy community - Traders Union
Lexicon Pharmaceuticals director Debbane buys $147,000 in stock - Investing.com Australia
Director buys 100K Lexicon (LXRX) shares at $1.47 in market trade - Stock Titan
Q1 2025 Lexicon Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Lexicon Pharmaceuticals Achieves 107.99% Annual Return, Establishing It as a Multibagger Stock - Markets Mojo
Aug Retail: Is DXC Technology Company forming a double bottom2025 Dividend Review & AI Forecasted Entry and Exit Points - baoquankhu1.vn
Raymond Debbane buys Lexicon Pharmaceuticals (LXRX) shares By Investing.com - Investing.com Australia
Raymond Debbane buys Lexicon Pharmaceuticals (LXRX) shares - Investing.com
Lexicon Pharmaceuticals (NASDAQ:LXRX) Director Buys $72,000.00 in Stock - MarketBeat
Insider Buying: Lexicon Pharmaceuticals (NASDAQ:LXRX) Director Purchases 100,000 Shares of Stock - MarketBeat
Lexicon Pharmaceuticals (LXRX) director buys 150,000 common shares - Stock Titan
Analysts Set Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Price Target at $3.23 - Defense World
How The Lexicon Pharmaceuticals (LXRX) Story Is Shifting With Fine Tuned Targets And Trials - Yahoo Finance
What is Lexicon Pharmaceuticals Inc.’s valuation compared to sectorEarnings Growth Summary & Weekly Watchlist for Consistent Profits - mfd.ru
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Artal Participations boosts Lexicon (NASDAQ: LXRX) stake with Series B preferred buy - Stock Titan
Lexicon Pharmaceuticals (LXRX) Sees Insider Buying Boost - GuruFocus
Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Gap UpHere's What Happened - MarketBeat
Lexicon Pharma stock spikes after insider buy (LXRX:NASDAQ) - Seeking Alpha
GSA Capital Partners LLP Sells 1,627,753 Shares of Lexicon Pharmaceuticals, Inc. $LXRX - MarketBeat
Lexicon (LXRX) grants major RSU and option awards to CMO - Stock Titan
Lexicon Pharma spikes after FDA feedback on pain drug - MSN
How rising interest rates impact Lexicon Pharmaceuticals Inc. stockQuarterly Profit Report & Weekly Setup with High ROI Potential - mfd.ru
LXRX PE Ratio & Valuation, Is LXRX Overvalued - Intellectia AI
LXRX Should I Buy - Intellectia AI
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Crosses Above 200 Day Moving AverageHere's Why - MarketBeat
Sentiment Recap: Does Lexicon Pharmaceuticals Inc meet Warren Buffetts criteriaTrade Risk Summary & Verified Momentum Stock Watchlist - baoquankhu1.vn
Lexicon Pharmaceuticals completes $100 million stock offering By Investing.com - Investing.com Nigeria
Lexicon Pharmaceuticals completes $100 million stock offering - Investing.com
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):